Kagoshima, Japan · Founded 2022 · Privately Held (backing)
Developer of gene therapies designed to improve the treatment of various diseases. Surv BioPharma is based in Kagoshima, Japan and was founded in 2022. Its last reported valuation was $32.5 million in Dec 2025. It has raised $21.3 million.
Last reported valuation
$32.5M
Oct 2026
Priced at
—
Total raised
$21.3M
Last round
—
Cap table — not yet on record
Surv BioPharma's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Surv BioPharma with a free account
·The complete investor list: 15 names
·Watch Surv BioPharma: the Monday email on marks, rounds and moves
